SE0300120D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0300120D0
SE0300120D0 SE0300120A SE0300120A SE0300120D0 SE 0300120 D0 SE0300120 D0 SE 0300120D0 SE 0300120 A SE0300120 A SE 0300120A SE 0300120 A SE0300120 A SE 0300120A SE 0300120 D0 SE0300120 D0 SE 0300120D0
Authority
SE
Sweden
Prior art keywords
sup
sub
alkyl
optionally substituted
nitrogen
Prior art date
Application number
SE0300120A
Other languages
English (en)
Swedish (sv)
Inventor
Martin Cooper
Simon Guile
Tony Ingall
Rukhsana Rasul
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0300120A priority Critical patent/SE0300120D0/xx
Publication of SE0300120D0 publication Critical patent/SE0300120D0/xx
Priority to RU2005121493/04A priority patent/RU2331646C2/ru
Priority to CNB2004800071016A priority patent/CN100358900C/zh
Priority to BR0406780-0A priority patent/BRPI0406780A/pt
Priority to JP2006500749A priority patent/JP4589298B2/ja
Priority to UAA200506375A priority patent/UA80175C2/uk
Priority to CA002512736A priority patent/CA2512736A1/en
Priority to AT04702471T priority patent/ATE375352T1/de
Priority to US10/542,194 priority patent/US7064126B2/en
Priority to ES04702471T priority patent/ES2293208T3/es
Priority to DE602004009407T priority patent/DE602004009407T2/de
Priority to EP04702471A priority patent/EP1587809B1/en
Priority to HK06102160.4A priority patent/HK1081958B/en
Priority to PL378223A priority patent/PL378223A1/pl
Priority to KR1020057013124A priority patent/KR20050092759A/ko
Priority to NZ541216A priority patent/NZ541216A/en
Priority to MXPA05007494A priority patent/MXPA05007494A/es
Priority to PCT/SE2004/000051 priority patent/WO2004065393A1/en
Priority to AU2004205617A priority patent/AU2004205617B2/en
Priority to IL169363A priority patent/IL169363A/en
Priority to ZA200505273A priority patent/ZA200505273B/xx
Priority to NO20053827A priority patent/NO20053827L/no
Priority to IS7982A priority patent/IS2503B/is
Priority to US11/447,343 priority patent/US20060223809A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
SE0300120A 2003-01-17 2003-01-17 Novel compounds SE0300120D0 (sv)

Priority Applications (24)

Application Number Priority Date Filing Date Title
SE0300120A SE0300120D0 (sv) 2003-01-17 2003-01-17 Novel compounds
AU2004205617A AU2004205617B2 (en) 2003-01-17 2004-01-15 Novel compounds
DE602004009407T DE602004009407T2 (de) 2003-01-17 2004-01-15 Thienopyridazinon-derivate als modulatoren von autoimmunkrankheiten
HK06102160.4A HK1081958B (en) 2003-01-17 2004-01-15 Thienopyridazinone derivative as modulators of autoimmune diseases
BR0406780-0A BRPI0406780A (pt) 2003-01-17 2004-01-15 Novos compostos
JP2006500749A JP4589298B2 (ja) 2003-01-17 2004-01-15 新規化合物
UAA200506375A UA80175C2 (en) 2003-01-17 2004-01-15 Thienopyridazinones, process for their preparation and their use in the modulation of autoimmune disease
CA002512736A CA2512736A1 (en) 2003-01-17 2004-01-15 Novel compounds
AT04702471T ATE375352T1 (de) 2003-01-17 2004-01-15 Thienopyridazinon-derivate als modulatoren von autoimmunkrankheiten
US10/542,194 US7064126B2 (en) 2003-01-17 2004-01-15 Compounds
ES04702471T ES2293208T3 (es) 2003-01-17 2004-01-15 Derivados de tienopiridazinona como moduladores de enfermedades autoinmunes.
RU2005121493/04A RU2331646C2 (ru) 2003-01-17 2004-01-15 Новые соединения
EP04702471A EP1587809B1 (en) 2003-01-17 2004-01-15 Thienopyridazinone derivative as modulators of autoimmune diseases
CNB2004800071016A CN100358900C (zh) 2003-01-17 2004-01-15 新化合物
PL378223A PL378223A1 (pl) 2003-01-17 2004-01-15 Nowe związki
KR1020057013124A KR20050092759A (ko) 2003-01-17 2004-01-15 신규 화합물
NZ541216A NZ541216A (en) 2003-01-17 2004-01-15 Thienopyridazinone derivatives as modulators of autoimmune diseases
MXPA05007494A MXPA05007494A (es) 2003-01-17 2004-01-15 Nuevos compuestos.
PCT/SE2004/000051 WO2004065393A1 (en) 2003-01-17 2004-01-15 Novel compounds
IL169363A IL169363A (en) 2003-01-17 2005-06-23 Thienopyridazinones, processes for their preparation, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
ZA200505273A ZA200505273B (en) 2003-01-17 2005-06-29 Novel compound
NO20053827A NO20053827L (no) 2003-01-17 2005-08-15 Nye forbindelser.
IS7982A IS2503B (is) 2003-01-17 2005-08-15 Ný efnasambönd
US11/447,343 US20060223809A1 (en) 2003-01-17 2006-06-06 Novel compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0300120A SE0300120D0 (sv) 2003-01-17 2003-01-17 Novel compounds

Publications (1)

Publication Number Publication Date
SE0300120D0 true SE0300120D0 (sv) 2003-01-17

Family

ID=20290155

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0300120A SE0300120D0 (sv) 2003-01-17 2003-01-17 Novel compounds

Country Status (22)

Country Link
US (2) US7064126B2 (enExample)
EP (1) EP1587809B1 (enExample)
JP (1) JP4589298B2 (enExample)
KR (1) KR20050092759A (enExample)
CN (1) CN100358900C (enExample)
AT (1) ATE375352T1 (enExample)
AU (1) AU2004205617B2 (enExample)
BR (1) BRPI0406780A (enExample)
CA (1) CA2512736A1 (enExample)
DE (1) DE602004009407T2 (enExample)
ES (1) ES2293208T3 (enExample)
IL (1) IL169363A (enExample)
IS (1) IS2503B (enExample)
MX (1) MXPA05007494A (enExample)
NO (1) NO20053827L (enExample)
NZ (1) NZ541216A (enExample)
PL (1) PL378223A1 (enExample)
RU (1) RU2331646C2 (enExample)
SE (1) SE0300120D0 (enExample)
UA (1) UA80175C2 (enExample)
WO (1) WO2004065393A1 (enExample)
ZA (1) ZA200505273B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
EP1587811A1 (en) * 2003-01-17 2005-10-26 AstraZeneca AB Thienopyridazinones and their use in modulation of autoimmune disease
SE0300119D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
ES2527118T3 (es) 2003-12-19 2015-01-20 Plexxikon Inc. Compuestos y procedimientos de desarrollo de moduladores de Ret
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
NZ563444A (en) 2005-05-17 2011-04-29 Plexxikon Inc Pyrrolo(2,3-b)pyridine derivatives as protein kinase inhibitors
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
CA2666603C (en) * 2006-10-16 2013-08-06 Pfizer Products Inc. Therapeutic pyrazolyl thienopyridines and uses thereof for treating tgf.beta. mediated conditions
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
RU2009122670A (ru) 2006-12-21 2011-01-27 Плекссикон, Инк. (Us) Соединения и способы для модуляции киназ и показания к их применению
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
EA022924B1 (ru) 2009-04-03 2016-03-31 Ф.Хоффманн-Ля Рош Аг ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
MA33975B1 (fr) 2009-11-06 2013-02-01 Plexxikon Inc Composés et méthodes de modulation des kinases et leurs indications d'emploi
JP5941069B2 (ja) 2011-02-07 2016-06-29 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節のための化合物および方法、ならびにそれに対する適応症
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
US9200005B2 (en) * 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
ES2890552T3 (es) * 2013-10-21 2022-01-20 Genosco Compuestos de pirimidina sustituidos y su uso como inhibidores de SYK

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3620860A1 (de) * 1986-06-21 1987-12-23 Basf Ag Substituierte acrylsaeureester und fungizide, die diese verbindungen enthalten
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6469014B1 (en) * 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
DE69807741T2 (de) * 1997-12-05 2004-07-15 Astrazeneca Uk Ltd. Neuartige verbindungen
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
ATE253580T1 (de) * 1998-08-28 2003-11-15 Astrazeneca Ab Neue thieno(2,3-d)pyrimidindione, verfahren für ihre herstellung und ihre verwendung in der therapie
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
EP1587811A1 (en) * 2003-01-17 2005-10-26 AstraZeneca AB Thienopyridazinones and their use in modulation of autoimmune disease

Also Published As

Publication number Publication date
AU2004205617B2 (en) 2007-03-08
NO20053827D0 (no) 2005-08-15
RU2005121493A (ru) 2006-02-20
UA80175C2 (en) 2007-08-27
MXPA05007494A (es) 2005-09-21
CA2512736A1 (en) 2004-08-05
DE602004009407D1 (de) 2007-11-22
RU2331646C2 (ru) 2008-08-20
JP4589298B2 (ja) 2010-12-01
NO20053827L (no) 2005-10-17
US7064126B2 (en) 2006-06-20
AU2004205617A1 (en) 2004-08-05
KR20050092759A (ko) 2005-09-22
CN100358900C (zh) 2008-01-02
BRPI0406780A (pt) 2006-01-17
ZA200505273B (en) 2006-04-26
HK1081958A1 (en) 2006-05-26
DE602004009407T2 (de) 2008-07-24
WO2004065393A1 (en) 2004-08-05
IL169363A0 (en) 2007-07-04
ATE375352T1 (de) 2007-10-15
EP1587809A1 (en) 2005-10-26
NZ541216A (en) 2008-05-30
US20060052380A1 (en) 2006-03-09
EP1587809B1 (en) 2007-10-10
CN1761670A (zh) 2006-04-19
ES2293208T3 (es) 2008-03-16
JP2006515373A (ja) 2006-05-25
PL378223A1 (pl) 2006-03-20
US20060223809A1 (en) 2006-10-05
IL169363A (en) 2011-02-28
IS2503B (is) 2009-04-15
IS7982A (is) 2005-08-15

Similar Documents

Publication Publication Date Title
SE0300120D0 (sv) Novel compounds
MXPA05007496A (es) Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes.
IS2598B (is) Þíenópýrimidíndíón og notkun þeirra í mótun sjálfnæmissjúkdóma
HUP0401009A2 (hu) 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
EA200600892A1 (ru) Новые хинолиновые производные
ATE334988T1 (de) Thieno 2,3-döpyrimidinediones als inhibitoren von t-zellen-proliferation
DE69406649D1 (de) N-alkyl-2-substituierte atp-analoge
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
PE20030257A1 (es) Analogos de 8-aza-11-desoxi-prostaglandina como agonistas del receptor ep4
HUP0500543A2 (hu) Piridonszármazékok mint aP2 inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
DE69501947D1 (de) SUBSTITUIERTE AROMATISCHE VERBINDUNGEN ALS c. AMP PHOSPHODIESTERASE-UND TNF-HEMMER
BR0010366A (pt) Composto, composição farmacêutica, método de preparar um composto, e, composto para uso em terapia
TW200716528A (en) Cyclopropanecarboxamide derivatives
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
EA200501148A1 (ru) Пиридилоксиметильные и бензизоксазольные азабициклические производные
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
MXPA04005426A (es) Derivados de pirazol de anillos fuisionados.
EA200001101A1 (ru) НОВЫЕ ДИГИДРОФУРО[3,4-b]ХИНОЛИН-1-ОНЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
ATE397609T1 (de) Corticotropinfreisetzungsfaktor antagonisten
NZ535183A (en) Fused bicyclic pyrimidine derivatives
DE60239324D1 (de) Phenyl- und pyridyl-piperidine mit tnf-wirkung
DK0514935T3 (da) Hidtil ukendte bensopyranderivater og fremgangsmåder til fremstilling deraf
ECSP034870A (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6